2 completed, 1 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow tedizolid phosphate: new trials by email Literature Review of tedizolid phosphate trials Research Report on tedizolid phosphate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB) Tedizolid arm (SIVEXTRO®), Linezolid arm (ZYVOXID®), Standard quadruple therapy arm - Tuberculosis, Multidrug Resistant Tuberculosis | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 60 | 2023-04-20 | 2025-02-03 |
| Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER) Tedizolid - Bone and Joint Infection | Phase 2 | Completed | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 44 | 2017-02-06 | 2023-12-13 |
| Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections TR-701 200 mg, TR-701 300 mg, TR-701 400 mg - Skin Diseases, Infectious, Skin Diseases, Bacterial | Phase 2 | Completed | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 192 | 2008-09-17 | 2019-11-25 |
Infections (1) · Osteomyelitis (1) · Skin Diseases, Bacterial (1) · Skin Diseases, Infectious (1) · Tuberculosis (1) · Tuberculosis, Multidrug-Resistant (1)
Assistance Publique - Hôpitaux de Paris (1) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)
United States (2) · France (1)
Loren G Miller, MD MPH (1) · Philippe Prokocimer, MD (1)